

	Fiscal 2016 Quarter Ended
(in thousands, except per share data)	March 31,		June 30,			September 30,			December 31,
Total revenue	$	19,127	$	20,747		$	25,118		$	25,722
Total gross profit		9,504		10,644			12,638			11,374
Total operating expenses		28,069		28,714			29,373			29,248
Loss from operations		(18,565)		(18,070)			(16,735)			(17,874)
Net loss		(19,352)		(18,499)			(17,494)			(19,030)
Basic and diluted net loss per share	$	(0.23)	$	(0.21)		$	(0.19)		$	(0.21)
Weighted average shares used in computing net loss per share (1)		83,604		88,148			92,110			92,660

	Fiscal 2015 Quarter Ended
	March 31,		June 30,			September 30,			December 31,
Total revenue	$	17,645	$	24,939	(2)	$	13,917		$	36,281	(2)
Total gross profit		5,927		14,506			6,551			26,466
Total operating expenses		25,255		25,864			3,937	(3)		27,528
Income (loss) from operations		(19,328)		(11,358)			2,614	(3)		(1,062)
Net income (loss)		(20,173)		(11,935)			1,821	(3)		(1,409)
Net income (loss) per share
Basic	$	(0.27)	$	(0.16)		$	0.02	(3)	$	(0.02)
Diluted	$	(0.27)	$	(0.16)		$	0.02	(3)	$	(0.02)
Weighted average shares used in computing net income (loss) per share (1)
Basic		74,149		74,733			75,205			78,327
Diluted		74,149		74,733			80,479			78,327

(1)

In 2015 and 2016 we established various “at-the-market” offerings pursuant to which we offered and sold shares of our common stock. See “Note 9. Stockholders’ Equity” for additional information

(2)

As provided in the Roche Agreement, we achieved the second and third (final) development milestones and recognized the related $10.0 million and $20.0 million, respectively, as contractual revenue during the quarters ended June 30, 2015 and December 31, 2015, respectively. See “Note 3. Contractual Revenue” for additional information.

(3)

For the quarter ended September 30, 2015, we recognized a one-time gain on lease amendments of $23.0 million, which was recorded in operating expenses on our statement of operations and comprehensive income (loss) for the period. See “Note 7. Commitments and Contingencies” for additional information.